Alzheimer’s Treatment Centers of America (ATCA) only treats Alzheimer’s, Dementia, Cognitive Impairment and Brain Fog from Long COVID, using Artificial Intelligence combined with Personalized Precision Medicine. In the study of its AI protocol, 75% of the patients had no further declinein their mild cognitive impairment.
Scope of the issue and addressable market
- 6.7 Million Americans live with Alzheimer’s disease.
- One in three seniors will die with dementia.
- The AI Protocol has identified over 100 Root Causes of Alzheimer’s disease.
- The USA Market Size for Alzheimer’s is $355 billion annually. The global market is over $1.5 trillion and is expected to triple by 2050.
Investors have commented that the company’s mission to treat Alzheimer’s, dementia, memory loss and brain fog from Long COVID is not only an investment with an excellent ROI, but also an impact investment that will reshape healthcare for the aging population.
ATCA is one of the many featured companies slated to present at The Microcap Conference 2024, set for Jan. 30-Feb. 1 at Caesars Atlantic City Hotel and Casino. This three-day conference presented by DealFlow Events features technical programming designed for microcap investors and a presenting company track for pitching and socializing.
How AI Transforms Treatment Protocols for Alzheimer’s
The company’s Artificial Intelligence (AI) tools create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines. Laboratory tests ordered by the Alzheimer’s Treatment Centers of America (ATCA) medical team along with DNA results, the patient’s health and family health history, including comorbidities, lifestyle habits and medications are uploaded to the AI platform.
The AI then does reverse correlation analysis against millions of records (Alzheimer’s, dementia, diabetes, chronic kidney disease, depression and other data from sources like NIH) and then assesses 50-plus risk factors, pinpointing areas of concern and ultimately generating a ~30 page personalized care plan with evidence-based, actionable treatment recommendations.
With insights from the report, the ATCA physicians may identify potentially reversible causes of cognitive decline, such as medication side effects or hormonal imbalances, heavy metals, inflammation, gut health issues, etc. to develop a personalized precision protocol for treating the patient. Care plans may include pharmacological treatment, supplementation-based treatment, specific modalities like hyperbaric oxygen or cryogenic therapies, and lifestyle habit recommendations including diet and exercise, which the physician and medical team/health coaches can use to inform the patient.
Business Status of Alzheimer’s Treatment Centers of America
The initial clinic has been constructed and equipped. ATCA is now in the process of transitioning to a brick-and-mortar setup, preparing to hire staff, implement marketing strategies, and scale up a 17,000 sq. ft. clinic in Atlanta. Successful alpha and beta testing have been completed. We have invested $1.5 million in onsite treatment tools. Additionally, there is a nutraceutical store onsite, along with a 20-chair infusion center.
ATCA is not a start-up, it’s a roll out and it is ready to scale. There is no more R & D to prove out. Alpha testing, Beta testing, R & D testing, and Marketing testing have all been successfully accomplished.
The company is in-network with Medicare and all major insurance and have been paid.
ATCA is a Unicorn investment. One of our medical doctors said that what Alzheimer’s Treatment Centers of America (ATCA) is doing in the field of Alzheimer’s and dementia treatment was not only disruptive but truly revolutionary.
Key Leadership
- 10 successful MBAs from Harvard (6) + Duke (1) MBA, Michigan (1), Wharton (1) and Copenhagen (1)
- 6 renowned Doctors from Harvard (2), Oxford, Columbia, Ohio State, Meharry + a Neurologist trained in functional medicine
- 3 world class influencers for marketing purposes with huge social media reach
Greg Buckley, CEO
MBA Harvard Business School
BSME University of Michigan
CEO: Progressive Medical Center
Grew revenue 330% in four years.
President: Progressive Insurance Company
Grew revenue 750% in five years.
Grew profit by 2100% in five years.
Vice President: PepsiCo’s Pizza Hut
1,500 locations under management
Opened 100 company stores over 2 years.
COO: Gibson Guitars
Dr. Joshua Helman – Chief Medical Officer
Dr. Helman is a Harvard-trained physician licensed in fourteen states. He has two degrees in Biochemistry, (Bachelor’s from Harvard magna cum laude and Master’s from the University of Cambridge, UK).
He is double Board Certified by the American Board of Emergency Medicine and American Board of Lifestyle Medicine. His medical degree is from Harvard Medical School and MIT. Dr. Helman is the former Medical Director of Hippocrates Health Institute, was on the TrueNorth Health Center research team and was affiliated with Sponaugle Wellness Institute for six years, helping to treat and prevent dementia.
A look to the future
Alzheimer’s disease is already a global pandemic. It is the number one cause of death in the United Kingdom, the Netherlands and Finland. It is the number six cause of death in the United States. Every three seconds, someone in the world is diagnosed with Alzheimer’s disease. ATCA’s goal is to reverse these grim statistics as it offers treatment solutions today. Learn more.
Tickets to the inaugural Microcap Conference 2024 are going fast. Reserve your seat now for three days of unsurpassed networking and technical discussions of the microcap sector with some of the best names in the business – institutional investors, finance-focused law firms, venture and private equity fund managers, deal advisors, PIPE funds, brokerage firms, investor relations professionals, accredited retail investors and many more. The conference schedule is also packed with entertainment and exciting activities set against the backdrop of Atlantic City’s bright lights.
Sponsored content, this is a paid promotion
Comments and opinions presented in DealFlow Events publications such as The Microcap Newsletter are solely those of the analysts, corporate executives, and others quoted. They do not represent the opinions of DealFlow Events and DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter.
